(ALXO) ALX Oncology Holdings Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALXO) ALX Oncology Holdings Inc. Complete Analysis Pack
ALX Oncology’s Business Model, Simplified for Investors
Unlock the full strategic blueprint behind ALX Oncology Holdings Inc.’s business model. This concise Business Model Canvas highlights how the company creates value, manages partnerships, and positions itself in a competitive biotech market. Ideal for investors, analysts, and strategists—get the full version for deeper insight.
Partnerships
Merck Phase 2 pembrolizumab collaboration
Merck is a core clinical partner for ALX Oncology Holdings Inc. through the Phase 2 ALX148 study with pembrolizumab, with or without chemotherapy, in head and neck cancer. This collaboration deepens combination data in solid tumors; Merck’s Keytruda posted $29.5 billion in 2024 sales, underscoring the scale of the checkpoint-inhibitor backbone.
Zymeworks Phase 1 zanidatamab trial
Zymeworks is a key partner in ALX Oncology Holdings Inc.’s Phase 1 zanidatamab study, combining ALX148 with the HER2-targeting bispecific antibody zanidatamab in HER2-expressing breast cancer and other solid tumors. This extends ALX Oncology Holdings Inc. beyond its core focus into HER2-driven disease settings and expands its clinical reach.
Tallac Therapeutics development alliance
Tallac Therapeutics is ALX Oncology Holdings Inc.’s partner for development, manufacturing, and commercialization of a novel cancer immunotherapeutics program, adding outside know-how and capacity beyond ALX Oncology Holdings Inc.’s internal team. This kind of alliance helps spread execution risk while extending the company’s reach without building every capability in-house.
Selexis SA licensing agreement
Selexis SA gives ALX Oncology Holdings Inc. licensing rights tied to cell line and biologics development tools, which matters because clinical-stage programs need a reliable path to GMP manufacturing. The deal supports scale-up readiness for ALX Oncology Holdings Inc. as it advances amagib enes, while the company still reported R&D spend of $67.8 million in 2025, showing why outside infrastructure access helps control internal build costs.
- Cell line licensing supports biologics scale-up
- Helps clinical manufacturing readiness
- Reduces need for in-house buildout
Crystal Bioscience licensing agreement
Crystal Bioscience, Inc. is a licensing partner that gives ALX Oncology Holdings Inc. access to rights that support its pipeline work. For a biotech, this kind of license can speed research and reduce internal build time because it secures enabling technology needed for development.
It is a practical fit for ALX Oncology Holdings Inc.’s business model: partner-sourced IP can broaden R&D reach without having to create every core tool in-house.
- Supports pipeline development
- Secures enabling technology rights
- Expands ALX Oncology Holdings Inc. R&D access
ALX Oncology Leans on Partners to Fuel Its Pipeline
ALX Oncology Holdings Inc. depends on external drug, manufacturing, and licensing partners to extend its pipeline without building every capability in-house. Merck, Zymeworks, Tallac Therapeutics, Selexis SA, and Crystal Bioscience, Inc. add trial depth, IP access, and scale-up support as ALX Oncology Holdings Inc. reported 2025 R&D spend of $67.8 million.
| Partner | Role |
|---|---|
| Merck | ALX148 combo trial |
| Selexis SA | Cell-line licensing |
What is included in the product
Detailed Word Document
A concise Business Model Canvas overview of ALX Oncology Holdings Inc., capturing its oncology-focused value proposition, partners, channels, and revenue logic.
Customizable Excel Spreadsheet
Quickly clarifies ALX Oncology’s business model pain points with a concise, editable one-page canvas.
Reference Sources
Provides a credible source trail for ALX Oncology Holdings Inc. claims, making due diligence faster and decisions easier to verify.
Activities
ALX148 Phase 1b/2 development
ALX Oncology’s main value-creation engine is ALX148 (evorpacept), which it is advancing in Phase 1b/2 studies across both hematologic malignancies and solid tumors. In 2025, this program remained the company’s core clinical focus, with one asset spanning 2 major cancer settings.
Combination trial execution
ALX Oncology uses combination trial execution to test ALX148 with established oncology drugs like pembrolizumab and zanidatamab, which has FDA accelerated approval since 2024. This work is central to the CD47-blocking strategy because it checks whether ALX148 can raise response rates and safety in real patients, not just in lab settings.
ALTA-002 preclinical development
In FY2025, ALX Oncology Holdings Inc. kept ALTA-002 as its preclinical portfolio asset: a SIRPa TRAAC built to engage both innate and adaptive immunity. This 1-asset program is a key activity because preclinical work is where the next wave of pipeline value is built before clinical spend starts.
Clinical operations and data generation
ALX Oncology Holdings Inc. runs patient enrollment, site coordination, and clinical data collection to keep studies moving across multiple indications. These operations turn trial activity into regulatory-grade evidence, and they are the backbone of the company’s readouts and label-expansion work.
- Enroll patients and manage sites
- Collect clean, trial-grade data
- Support multi-indication readouts
Manufacturing and collaboration management
ALX Oncology Holdings Inc. keeps manufacturing and CMC work tightly coordinated with partner-led development, so small internal teams can still advance multiple programs at once. This matters because the Company had 2 clinical-stage programs in its pipeline, making external execution control central to speed and cost discipline.
Runs CMC and partner work together
Manages external collaborators across programs
Supports pipeline progress with lean scale
ALX Oncology Advances Two Clinical Programs in FY2025
In FY2025, ALX Oncology Holdings Inc. focused on advancing 2 clinical-stage programs: ALX148 (evorpacept) in Phase 1b/2 studies across hematologic malignancies and solid tumors, plus ALTA-002 in preclinical work. Its key activities were trial execution, patient/site management, data capture, and partner-led CMC support for combination studies with pembrolizumab and zanidatamab.
| Key activity | FY2025 fact |
|---|---|
| Clinical development | 2 clinical-stage programs |
| ALX148 trials | Phase 1b/2, 2 cancer settings |
Full Document Unlocks After Purchase
Business Model Canvas
The ALX Oncology Holdings Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It’s not a mockup or sample—what you’re viewing is a live section of the final file, with the same structure and content. Once you complete your order, you’ll get full access to this same ready-to-use document, exactly as shown.
Resources
ALX148 lead candidate
ALX148 (evorpacept) is ALX Oncology Holdings Inc.'s lead asset and a CD47-blocking candidate in clinical development. It anchors the pipeline strategy, with Company Name reporting no product revenue and a cash position of $107.4 million as of December 31, 2024.
ALTA-002 pre-clinical asset
ALTA-002 is ALX Oncology Holdings Inc.'s second named pipeline program and adds a second asset to a pipeline that has been anchored by ALX148. As a SIRPa TRAAC platform candidate, it broadens the Company’s biologic depth and gives the business model 2 disclosed programs instead of 1.
Clinical-stage data package
ALX Oncology Holdings Inc.’s key resource is its clinical-stage data package, built from ongoing Phase 1b/2 and Phase 1 studies that feed decisions across hematologic and solid tumors. This clinical evidence is the core asset for selecting doses, signals, and next-step programs, with two active trial stages shaping the pipeline.
Licensed IP and platform rights
ALX Oncology Holdings Inc. relies on licensed IP and platform rights from Selexis SA and Crystal Bioscience to support its research base, process development, and later manufacturing access. In biologics, control of cell-line and platform IP is a key gatekeeper: ALX Oncology Holdings Inc. spent $105.9 million on R&D in 2025, so these rights help protect that investment and keep the path to commercialization open.
- Selexis SA and Crystal Bioscience underpin development.
- IP access supports research and manufacturing.
- Biologics value depends on protected platform rights.
South San Francisco headquarters
ALX Oncology Holdings Inc. is based in South San Francisco, California, at the center of one of the U.S. biotech hubs. The city hosts 200+ life sciences companies, so the headquarters gives ALX Oncology Holdings Inc. direct access to biotech talent, CROs, and lab infrastructure.
- 200+ biotech and life sciences firms nearby
- Stronger hiring and partner access
- Fast links to Bay Area infrastructure
ALX Oncology’s Pipeline and Cash Fuel Early-Stage Progress
ALX Oncology Holdings Inc.’s key resources are its clinical pipeline, led by ALX148 and ALTA-002, plus licensed platform IP from Selexis SA and Crystal Bioscience. These assets are backed by $105.9 million in R&D spend in 2025 and $107.4 million in cash at December 31, 2024, which funded ongoing Phase 1b/2 and Phase 1 work.
| Resource | Data |
|---|---|
| R&D 2025 | $105.9M |
| Cash 2024 | $107.4M |
| Named programs | 2 |
Value Propositions
CD47-blocking immunotherapy
ALX148 is ALX Oncology Holdings Inc.’s CD47-blocking therapeutic, designed to stop the CD47 “don’t eat me” signal that many cancer cells use to escape immune attack. It offers a differentiated immuno-oncology mechanism, with the company advancing it in clinical development as a targeted way to restore anti-tumor immune activity.
Broad hematologic and solid tumor coverage
ALX Oncology Holdings Inc. targets myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and multiple solid tumors, giving evorpacept several shots on goal across blood and solid cancers. That breadth matters in a market with more than 20 million new cancer cases a year worldwide, and it can widen the addressable oncology pool as each program moves through the clinic.
Combination potential with standard oncology drugs
ALX148 (evorpacept) is being tested with pembrolizumab and zanidatamab, pairing a myeloid checkpoint blocker with standard oncology drugs to lift anti-tumor activity. This combo-first design can fit more real-world regimens, since pembrolizumab is used across many solid tumors and zanidatamab reached FDA accelerated approval in 2024.
Novel SIRPa TRAAC platform
ALTA-002 adds a second ALX Oncology Holdings Inc. platform with a distinct SIRPa TRAAC mechanism, designed to activate both innate and adaptive immunity. That widens the pipeline beyond one program and supports a longer-term innovation story built on 2 distinct immune-oncology platforms.
- Second platform, distinct mechanism
- Engages innate and adaptive immunity
- Broadens long-term pipeline optionality
Pipeline designed for high unmet need cancers
ALX Oncology Holdings Inc. focuses its pipeline on cancers with major unmet need, led by evorpacept, a CD47 blocker being studied in blood cancers and hard-to-treat solid tumors. In 2024, the company reported cash, cash equivalents, and short-term investments of $142.7 million, supporting a strategy aimed at clinically meaningful gaps where standard options remain limited.
- Targets high unmet need cancers
- Lead program spans blood and solid tumors
- Focuses on clinically meaningful gaps
ALX Oncology’s CD47 Platform and $142.7M Cash Fuel Growth
ALX Oncology Holdings Inc.’s value proposition is a differentiated CD47-blocking immuno-oncology platform, led by evorpacept, built to pair with standard drugs and expand use across blood and solid tumors. The company also adds ALTA-002, a second immune platform, while ending 2024 with $142.7 million in cash, cash equivalents, and short-term investments.
| Value driver | Data |
|---|---|
| Lead asset | Evorpacept (ALX148) |
| Pipeline breadth | MDS, AML, NHL, solid tumors |
| Liquidity | $142.7M (2024) |
Customer Relationships
Co-development partnerships
ALX Oncology uses co-development to build long-term customer ties, sharing development work and data generation with partners such as Merck, Zymeworks, and Tallac, three named collaborations in this model. This approach spreads R&D effort and keeps external partners close to its pipeline as programs move through the clinic.
Clinical site collaboration
ALX Oncology Holdings Inc. relies on oncology trial sites and investigators to fill studies, run protocols, and keep data clean; in clinical-stage biotech, site execution can make or break timelines. Its lead program evorpacept was still being tested across multiple solid-tumor and blood-cancer studies in 2025, so strong site ties directly affect enrollment speed and readout quality.
Scientific and regulatory engagement
ALX Oncology Holdings Inc. keeps scientific dialogue active with investigators and key opinion leaders to sharpen trial design, endpoints, and readouts. This evidence-led approach supports late-stage regulatory meetings and filings, especially as the company advances its lead programs through clinical development.
Its customer relationships are built around data: efficacy, safety, and biomarker evidence that regulators can assess. That matters in oncology, where one strong dataset can decide whether a program moves from Phase 2 into pivotal testing and, later, approval.
Data-driven patient support model
ALX Oncology Holdings Inc. keeps patient ties mostly inside clinical sites, where investigators manage consent, safety checks, and strict protocol adherence across hematologic and solid-tumor trials. That model fits an early-stage biotech: trust is built through trial centers, and the key relationship metric is clean data plus low serious adverse event risk.
Patient contact runs through trial investigators.
Safety drives retention and compliance.
Trial data quality is the core value.
Investor and public-market communication
ALX Oncology Holdings Inc. keeps investor ties through SEC filings and corporate updates, with at least 1 annual 10-K, 3 quarterly 10-Qs, and current 8-Ks each year. That recurring cadence gives investors a steady view of pipeline progress, partnership activity, and capital use, so the relationship is built on ongoing disclosure, not one-off outreach.
- Recurring SEC filings support transparency
- Quarterly updates track pipeline progress
- Corporate news covers partnership activity
ALX Builds Trust Through Trials, Transparency, and Partnerships
ALX Oncology Holdings Inc. builds customer relationships mainly through trial sites, investigators, KOLs, and partners, so trust rests on clean data, safety, and fast enrollment. In 2025, its disclosure cycle stayed investor-friendly with 1 annual 10-K, 3 quarterly 10-Qs, and current 8-K updates, while partner ties with Merck, Zymeworks, and Tallac supported co-development.
| Relationship | 2025 signal |
|---|---|
| Trial sites | Enrollment and data quality |
| Investors | 1 10-K, 3 10-Qs, 8-Ks |
| Partners | 3 named collaborations |
Channels
Clinical trial sites
Clinical trial sites are ALX Oncology Holdings Inc.'s main patient access channel, because they drive enrollment, dosing, and endpoint data capture across its phase 1/2 pipeline. In oncology, site execution is critical: the faster sites open and recruit, the faster the Company can move evorpacept studies toward readouts and partnering decisions.
Partner company networks
ALX Oncology Holdings Inc. uses partner company networks as distribution-like collaboration channels, with 5 named partners: Merck, Zymeworks, Tallac, Selexis, and Crystal Bioscience. These links help run combination studies and licensing-backed development, widening reach without ALX Oncology having to build every trial or platform alone.
Scientific conferences and publications
ALX Oncology Holdings Inc. can share trial updates at major medical meetings like ASCO, which draws about 40,000 oncology professionals, and through peer-reviewed journals. These channels reach investigators, oncologists, and industry experts fast, so visible data releases matter for trust and uptake.
Corporate website and SEC filings
ALX Oncology Holdings Inc. uses its corporate website and SEC filings as standard investor channels, with 1 annual Form 10-K and 4 quarterly Form 10-Q updates each year. These public disclosures formally communicate pipeline progress, partnerships, strategy, and risk factors to the market.
- Formal SEC disclosure channel
- Shares pipeline and partnership updates
- Supports investor access and oversight
The website also centralizes presentations, news releases, and filing links, so stakeholders can track changes quickly without waiting for direct outreach.
Investor relations
Investor relations is ALX Oncology Holdings Inc.'s link to capital providers, and it matters most while the Company is still pre-commercial. It keeps investors updated on clinical milestones and partnership progress; as a clinical-stage biotech, ALX Oncology said it had $131.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025.
- Shares trial updates.
- Builds trust with capital providers.
- Supports funding before sales start.
ALX Oncology’s Key Channels Power Trial Progress and Cash Runway
ALX Oncology Holdings Inc.'s Channels are mainly clinical trial sites, partner networks, scientific meetings, and investor relations. These channels move evorpacept data to regulators, physicians, and capital providers; as of March 31, 2025, the Company held $131.8 million in cash, cash equivalents, and marketable securities, which makes clear why timely disclosure matters.
| Channel | Role | Latest data |
|---|---|---|
| Trial sites | Enroll and dose patients | Phase 1/2 pipeline |
| Investor relations | Funds pre-revenue ops | $131.8 million cash |
Customer Segments
Hematologic malignancy patients
Hematologic malignancies are a high-need segment for ALX Oncology Holdings Inc.'s lead program, which is being tested in myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin's lymphoma. AML alone causes about 11,000 U.S. deaths a year, showing the scale of unmet need in blood cancers.
Solid tumor patients
Solid tumor patients are a broad, high-need customer segment for ALX Oncology Holdings Inc. ALX148, or evorpacept, is in trials in head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction cancer, and HER2-expressing breast cancer. These large markets matter: global 2022 incidence was about 2.3 million for breast cancer, 970,000 for gastric cancer, and 890,000 for head and neck cancers.
Oncology investigators and trial centers
Academic and clinical cancer centers are core customers for ALX Oncology Holdings Inc. They enroll patients, run protocol-heavy studies, and generate the safety and efficacy data needed for clinical development; without site support, oncology trials do not move.
These centers also shape program speed and quality, since investigator-led enrollment and data capture drive readouts in Phase 1 to Phase 3 studies. For ALX Oncology Holdings Inc., each active trial site is a gatekeeper for patient access and trial execution.
Biopharma collaboration partners
Biopharma collaboration partners are a core B2B segment for ALX Oncology Holdings Inc.: Merck, Zymeworks, and Tallac are commercial partners that help validate and extend ALX Oncology’s assets, not just research contacts. That makes this segment a direct route to external proof, pipeline reach, and future value creation.
- 3 named commercial partners
- Validate ALX Oncology assets
- Support B2B value creation
Oncologists and cancer care providers
Oncologists and cancer care providers are ALX Oncology Holdings Inc.’s key future prescribers and clinical gatekeepers, because adoption will hinge on clear efficacy, safety, and combination use in real practice. Cancer burden stays huge: the IARC estimated about 20 million new cases and 9.7 million deaths in 2022, so even small gains in response or tolerability can matter for treatment choice.
- Future prescribers and trial influencers
- Need strong efficacy and safety data
- Combination utility drives uptake
They are the main downstream segment for commercialization, since their guideline, hospital, and referral decisions shape patient access. For ALX Oncology, winning this group means proving value in late-stage studies and showing use in regimens that fit current oncology workflows.
ALX Oncology’s Key Audience: Patients, Trial Sites, and Partners
ALX Oncology Holdings Inc. mainly serves cancer patients with high unmet need in hematologic and solid tumors, while academic cancer centers and oncologists drive trial access and future use. Its partners, including Merck, Zymeworks, and Tallac, also matter because they extend validation and pipeline reach.
| Segment | Why it matters |
|---|---|
| Patients | High-need blood and solid tumors |
| Sites | Run trials and enroll patients |
| Partners | Validate and expand assets |
Cost Structure
Clinical trial operations
Clinical trial operations are a major cost driver for ALX Oncology Holdings Inc., covering site management, patient enrollment, monitoring, and data capture. These costs usually step up in Phase 1b/2 and Phase 2 studies because more sites and patients mean higher per-trial spend, and for a clinical-stage biotech they can account for most R&D cash burn.
Research and development payroll
ALX Oncology Holdings Inc. is a clinical-stage biotech, so research and development payroll for scientific, clinical, and translational staff is a core cost and usually the biggest operating line. In FY2025, that labor-backed R&D spend sat at the center of its cost base, because drug development depends more on specialized people than on physical assets.
Manufacturing and CMC
ALX Oncology Holdings Inc. must fund process development, supply, formulation, and quality systems for its biologics pipeline, so Manufacturing and CMC is a core cost driver. This work keeps clinical trials supplied and builds launch readiness, and for a clinical-stage biotech like ALX Oncology, these costs typically sit alongside heavy R&D spending and can reach tens of millions of dollars a year.
Licensing and collaboration obligations
ALX Oncology Holdings Inc. has licensing and collaboration agreements with external partners, so its cost base can include upfront fees, milestone payments, and ongoing shared development खर्चs. In partnered programs, each side funds part of the work, which keeps R&D spend tied to deal terms and trial progress.
These obligations can turn into variable cash outflows fast, especially when a program advances. The latest public filings should be checked for specific 2025/2026 milestone commitments and royalty rates, since those are the numbers that move this cost line.
- Upfront license fees
- Milestone-linked payments
- Shared R&D funding
General and administrative costs
ALX Oncology Holdings Inc. carries recurring general and administrative overhead for finance, legal, compliance, board support, and investor relations, so this cost base stays sticky even when R&D moves. In FY2025, these public-company costs remained a fixed drain on cash burn because SEC reporting, audit, and governance work do not scale down fast.
- Finance, legal, compliance
- Investor relations and audit
- Fixed public-company overhead
ALX Oncology’s Burn Is R&D Heavy, With G&A Staying Sticky
ALX Oncology Holdings Inc.’s cost structure is dominated by R&D, with clinical trials, scientific payroll, and CMC work driving most cash burn in FY2025. Partnered programs add milestone and shared-development costs, while G&A stays sticky because public-company reporting, audit, legal, and compliance costs do not fall quickly.
| Cost item | Type |
|---|---|
| Clinical trials | Variable |
| R&D payroll | Fixed |
| CMC and supply | Mixed |
| G&A overhead | Fixed |
Revenue Streams
Collaboration payments
ALX Oncology Holdings Inc. can receive collaboration payments from development partners to fund shared studies and programs, which matters because fiscal 2025 product revenue was $0. For a pre-commercial biotech, this partner cash helps cover R&D and extends runway while evorpacept remains in development.
Upfront license fees
For ALX Oncology Holdings Inc., upfront license fees can bring in immediate cash from technology or platform access deals, which matters while the Company is still funding heavy R&D. In its latest filings, the Company remains pre-commercial, so even a single licensing payment can help offset early-stage research spend without adding as much dilution.
Development milestones
Development milestones are a key biotech revenue stream, with cash tied to clinical and regulatory steps like Phase 2/3 readouts and FDA filings. ALX Oncology had no product sales in 2025, so milestone payments remain an important non-dilutive source as its pipeline advances.
Royalties
ALX Oncology Holdings Inc. has no reported royalty revenue in FY2025, so this stream is still contingent on future partnered-product success. If a partner commercializes a licensed asset, royalties can become a long-duration biotech cash flow; for now, the model remains pre-commercial and tied to clinical and deal outcomes.
- FY2025 royalty revenue: $0
- Depends on partner commercialization
- Long-duration biotech income stream
Future product sales
ALX148 and related pipeline assets could become commercial products if ALX Oncology Holdings Inc. gets approval, but today the business is still partnership- and development-led. Product sales are the long-term prize, while the latest reported revenue mix still showed no product sales, so the stream remains pre-commercial.
- ALX148 is not yet approved.
- Product sales are the main upside.
- Current cash comes from partnerships.
- No commercial product revenue yet.
ALX Oncology’s Revenue Still Depends on Partnerships, Not Product Sales
ALX Oncology Holdings Inc. is still a pre-commercial biotech, so revenue in FY2025 came from collaboration and other partnership-related payments, not product sales. With FY2025 product revenue at $0, future cash flow still depends on licenses, milestones, and eventual commercialization of evorpacept.
| Revenue stream | FY2025 | Status |
|---|---|---|
| Product sales | $0 | None |
| Collaboration cash | Partner-funded | Active |
| Milestones, royalties | $0 reported | Future-linked |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.